Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherNon-Current ReceivablesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

ImmunityBio (IBRX) Receivables - Net (2016 - 2025)

ImmunityBio (IBRX) has disclosed Receivables - Net for 7 consecutive years, with $42.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Receivables - Net rose 1703.86% to $42.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $42.6 million, a 1703.86% increase, with the full-year FY2025 number at $42.6 million, up 1703.86% from a year prior.
  • Receivables - Net was $42.6 million for Q4 2025 at ImmunityBio, up from $32.0 million in the prior quarter.
  • In the past five years, Receivables - Net ranged from a high of $42.6 million in Q4 2025 to a low of $600000.0 in Q2 2023.
  • A 4-year average of $11.3 million and a median of $2.4 million in 2024 define the central range for Receivables - Net.
  • Peak YoY movement for Receivables - Net: skyrocketed 72.17% in 2024, then surged 2332.71% in 2025.
  • ImmunityBio's Receivables - Net stood at $1.3 million in 2022, then plummeted by 30.77% to $900000.0 in 2023, then soared by 162.22% to $2.4 million in 2024, then soared by 1703.86% to $42.6 million in 2025.
  • Per Business Quant, the three most recent readings for IBRX's Receivables - Net are $42.6 million (Q4 2025), $32.0 million (Q3 2025), and $22.1 million (Q2 2025).